I took two grams of mushrooms before heading out into the forest.
It was around 5:30 a.m. and the cool, morning rains were just starting to fade and transition into the warm blanket of an orange peel sunrise.
The bird songs were oddly melodic, my water jug was full, and it didn’t take long for me to start melting into my surroundings.
The fruit of the staghorn sumac was glowing, and I could taste the sun-brewed staghorn tea that I’d make this summer. I could even smell the raw wildflower honey and sprigs of mint that I always use to liven up the extract.
If you’ve never had it before, it’s very similar to lemonade. But up here in North Country, we don’t grow lemons. And staghorn sumac is so hearty, it mocks the harsh winters and wet springs.
I’m pretty sure that if an atom bomb landed squarely in the middle of Lake Champlain, the only thing remaining would be roaches and Staghorns.
I actually thought about this quite a bit on my journey.
Propped up against the withered white bark of an old yellow birch tree and gazing at all the beauty God created, I got lost in those Staghorn fruits, hypnotized by the intricacies of their soft, fuzzy clusters and geometric shapes.
And I started thinking about how this particular tree, which is littered all over the Adirondacks, is also common in the Middle East.
Culturally, these worlds couldn’t be more different. Yet, here we are –– two complete universes separated by dirt, water, and politics –– but feasting upon the same fruit without any thought of physical distance or climatic diversity.
Disconnected by language, culture, and war but completely connected by nature.
Not to get all treehugger on you, but that experience really made me want to share a cup of sumac tea, with some like-minded Persians at a corner cafe in Tehran.
Yes, as you can imagine, it was a pleasant journey.
But these days, magic mushrooms are no longer being sought out solely by folks like me who simply enjoy a pleasant, psychedelic experience. They’re being used to treat mental illness and with great success.
Crisis Equals Opportunity
Last year, you may have seen the segment that 60 Minutes produced, which focused on psychedelic medicines.
During that segment, the world learned about a new treatment for smoking addiction that boasted an 86% success rate.
For the sake of comparison, the most successful pharmaceutical currently on the market enjoys a 35% success rate. If “success,” is what you want to call it.
The fact is, this country has a very serious mental illness and drug addiction crisis. And it’s going to get worse.
As reported by the Washington Post, the coronavirus pandemic is pushing America into a mental health crisis:
Nearly half of Americans report the coronavirus crisis is harming their mental health, according to a Kaiser Family Foundation poll. A federal emergency hotline for people in emotional distress registered a more than 1,000 percent increase in April compared with the same time last year. Last month, roughly 20,000 people texted that hotline, run by the Substance Abuse and Mental Health Services Administration.
Online therapy company Talkspace reported, a 65% jump in clients since mid-February. Text messages and transcribed therapy sessions collected anonymously by the company show coronavirus-related anxiety dominating patients’ concerns.
If we don’t do something about it now, people are going to be suffering from these mental-health impacts for years to come, said Paul Gionfriddo, president of the advocacy group Mental Health America. That could further harm the economy as stress and anxiety debilitate some workers and further strain the medical system as people go to emergency rooms with panic attacks, overdoses and depression, he said.
Just as the country took drastic steps to prevent hospitals from being overwhelmed by infections, experts say, it needs to brace for the coming wave of behavioral health needs.
Not to sound crass, but the reality is that there’s never been a better time to bring to market new and potentially better treatments for mental illness. Certainly the FDA thinks so, as it has fast-tracked a number of new psychedelic medicines for clinical trials. And more are coming.
Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.
This is great news for those who do suffer from mental illness and addiction.
And it’s also great news for investors.
You see, in addition to the hundreds of studies that suggest there are some very real benefits to treating mental illness and addiction with psychedelics…
And in addition to new psychedelics decriminalization bills being introduced, debated, and yes, passed…
And in addition to an overall loosening of stigmas regarding illegal drugs around the world…
Millionaires and Billionaires Are Now Investing in Psychedelics
Perhaps the most well-known is entrepreneur Peter Thiel, who happens to boast a net worth of $2.3 billion.
Thiel recently ponied up big time to get a piece of ATAI Life Sciences, which is a biotech company developing psychedelic medicines for a variety of mental health issues.
Other stinking-rich investors who have recently put up their own millions in the psychedelics space include former CEO of Canopy Growth Corporation Bruce Linton (who amassed more than $200 million during his time with the company) and Shark Tank celebrity investor Kevin O’Leary, who boasts a net worth of about $400 million.
There are more, but those are probably the most well-known and have no problem with people knowing about their investments in the psychedelics space.
Others aren’t so public, and I know some of them.
From elite family offices to high rollers in Silicon Valley, a lot of cash is starting to pour into this space. And when the rich folks start showing up to these parties, you know something big is about to go down.
I’ll have more on this burgeoning opportunity in the coming weeks.
To a new way of life and a new generation of wealth…
Jeff is the founder and managing editor of Green Chip Stocks. For more on Jeff, go to his editor’s page.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.